To study the effects of M-CSF administration on longterm outcomes of unrelated BMT, we retrospectively analyzed data from patients transplanted through the Japan Marrow Donor Program. We obtained data from 54 patients who received M-CSF just after BMT and 500 patients who did not receive M-CSF or G-CSF acted as controls. There were no significant differences between the two cohorts with respect to OS, acute GVHD or relapse. Although the incidence of chronic GVHD was comparable between the two groups, extensive chronic GVHD was observed significantly less often in the M-CSF cohort than in the control group. Multivariate analysis identified M-CSF as a significant factor for attenuating extensive chronic GVHD (relative risk: 0.73; 95% confidence interval: 0.55-0.94; P ¼ 0.012). We also found the same results in matched-pair analysis. Our observation suggests the potential for clinical use of M-CSF to dampen severe chronic GVHD.
Introduction
Chronic GVHD is a major barrier to successful hematopoietic SCT. Because immunosuppressive treatment is necessary for extensive chronic GVHD, it remains a major cause of late death despite its association with lower relapse rates. 1, 2 Its pathophysiology is poorly understood, and management strategies beyond systemic corticosteroids have not been established. Neither thalidomide nor prolonged use of calcineurin inhibitors have been successful in preventing chronic GVHD. [3] [4] [5] M-CSF, a growth factor for cells from the monocytemacrophage lineage, has been used after chemotherapy and BMT to induce the early recovery of neutrophils and to reduce the incidence of febrile neutropenia. 6, 7 A tolerogenic action of M-CSF was reported during the induction of DCs from cord blood. 8, 9 Most recently, M-CSF administration before conditioning reduced the severity of GVHD in a mouse model, and it is anticipated that this modality may be adopted as a new strategy for preventing GVHD. 10 In this study, we retrospectively analyzed data from patients who underwent unrelated BMT through the Japan Marrow Donor Program to study effects of M-CSF administration on long-term outcomes of UR-BMT, and we identified decreased severity of chronic GVHD after M-CSF administration.
Materials and methods
We retrospectively analyzed data from patients who had undergone their first BMT through the Japan Marrow Donor Program between 1993 and 2005 and for whom complete data concerning age, sex, HLA compatibility and M-CSF treatment were available. Acute leukemia, malignant lymphoma and multiple myeloma in the first or second remission, CML in the first or second chronic phase and MDS without leukemic transformation were considered standard-risk diseases, whereas other hematological malignant diseases were considered high-risk diseases. Chronic GVHD was classified as having limited (involving only localized skin and/or liver) or extensive (generalized skin or limited disease plus involvement of other organs) involvement. Diseases that are not malignant were considered benign diseases. Informed consent was obtained from patients and donors in accordance with the Declaration of Helsinki, and approval of the study protocol was obtained from the JMDP Institutional Review Board.
Statistical analysis was performed with JMP (version 5.1; SAS Institute Inc., Cary, NC, USA) and R software (www.r-project.org/). OS was analyzed by the KaplanMeier method, and the log rank test was used to test the significance of differences. The incidence of GVHD and relapse was estimated by the cumulative incidence method considering death without GVHD and death without relapse as competing risks, respectively, according to EBMT statistical guidelines (http://www.ebmt.org/1WhatisEBMT/ Op_Manual/OPMAN_StatGuidelines_oct2003.pdf). The incidence of chronic GVHD was evaluated in patients who survived more than 100 days after transplantation. Factors that significantly affected chronic GVHD were evaluated by the Cox proportional hazards model. For matched-pair analysis, one or two patients were selected from the control cohort by closely matching for recipient age and gender, donor age and gender, disease risk, GVHD prophylaxis, ATG administration, era of transplantation and HLA compatibility.
Results
Fifty-four patients received M-CSF administration within 8 days of undergoing a BMT for a median length of 13 days, and data from 500 patients who received no CSF were used as the control. Forty-five patients started M-CSF injection on the first day after completing BMT. There were no significant differences in the patients' ages or sex, the donors' ages, ATG administration, infused nucleated cell number, GVHD prophylaxis or HLA compatibility ( Table 1 ). The M-CSF cohort (M) group received more transplants from male donors (M, 77.8% vs control, 62.3%; P ¼ 0.020) in the nineties (M, 57.4% vs control, 35.8%; P ¼ 0.002), and contained more standard-risk diseases than the control cohort (M, 64.8% vs control, 47.8%; P ¼ 0.014). Attenuation of chronic GVHD after M-CSF F Kimura et al OS of the M cohort group was superior to that of the control cohort (Figure 1a ; M, 57.7% vs control, 46.4% at 5 years after transplantation), but the difference was not significant (log rank test, P ¼ 0.084). There were no significant differences in the incidence or grade of acute GVHD between the two cohorts (Gray test, all acute GVHD, P ¼ 0.316; grade 2-4, P ¼ 0.691; grade 3-4, P ¼ 0.855).
The incidence of chronic GVHD was comparable in the two cohorts (Figure 1b ; Gray test, P ¼ 0.903). The incidence of extensive chronic GVHD of the M cohort was significantly lower than in the control (Figure 1c ; Gray test, P ¼ 0.021). The observed occurrence of extensive chronic GVHD was 8.9% in the M cohort and 24.3% in the control. Multivariate analysis revealed that M-CSF administration was a significant factor, as was the age of patients and donors, underlying disease and acute GVHD ( Table 2) . Although chronic GVHD is associated with a lower relapse rate of the underlying malignant disease, we did not observe any increase of relapse rate in the M cohort (Figure 1d ; Gray test, P ¼ 0.533).
We also performed matched-pair analysis with M-CSFtreated patients and identified a significant decrease in extensive chronic GVHD (Figure 2b ; Gray test, Po0.001). The incidence of chronic GVHD was lower in the M cohort without significance (Figure 2a ; Gray test, P ¼ 0.066). There were no significant differences in the incidence or grade of acute GVHD (Gray test, all acute GVHD, P ¼ 0.345; grade 2-4, P ¼ 0.333; grade 3-4, P ¼ 0.303).
Discussion
M-CSF is one of the cytokines that increases after BMT, and is reported to be associated with the development of acute GVHD in children. 11 Therefore, there was a possibility that M-CSF administration might have caused an increase in the severity of acute GVHD, but instead we observed a decrease in the severity of chronic GVHD. In patients with chronic GVHD, both the serum IL-10 level and IL-10 production from mononuclear cells have been shown to decrease after stimulation. [12] [13] [14] After stimulation with lipopolysaccharide, M-CSF-induced macrophages produce large amounts of IL-10 instead of IL-12. 15 Recent reports have shown that M-CSF induced DCs with IL-4 in a culture from human cord blood, and that these DCs produced high amounts of IL-10, but not IL-12, a pattern similar to that seen in M-CSF-induced macrophages. 8, 9 The low incidence and severity of both acute and chronic GVHD after cord blood transplantation irrespective of HLA disparity, has been well documented. [16] [17] [18] M-CSF is elevated during pregnancy and in cord blood. 19, 20 Taken together, the above information offers possible explanations for low incidence and severity of GVHD in cord blood transplantation. In this context, our observation suggests that M-CSF administration after UR-BMT might decrease severity of chronic GVHD, through induction of certain types of macrophages and DCs.
Very recently, Hashimoto et al. 10 revealed that host macrophages persist in the spleen and lymph nodes after conditioning to reduce allo-reactive donor T cells. Pretransplant administration of M-CSF limited expansion of donor allo-reactive T cells and improved GVHD outcome in a mouse model. Similarly, M-CSF administration in our analysis might have induced host macrophages to engulf donor T cells.
The present study raises the possibility that M-CSF administration after BMT might be used to control chronic GVHD, although some issues remain to be resolved. First, our study was a retrospective analysis, and a prospective Table 2 Multivariate analysis for extended type chronic GVHD using Cox proportional hazard modeling
Factor
Relative risk (95% CI) P The gender of patients and donors, donor-recipient sex-matching, ATG, administration, GVHD prophylaxis, HLA compatibility and era of transplantation had no significant effect. Attenuation of chronic GVHD after M-CSF F Kimura et al randomized study is necessary to further evaluate the effects of M-CSF. Second, we used classical diagnostic criteria and severity classifications of chronic GVHD, and did not distinguish between late onset acute GVHD and classic chronic GVHD. Nor did we use the global scoring system that the National Institute of Health consensus development project proposed. 21 Third, most patients started M-CSF injection beginning on the first day after transplantation. Donor T cells are engulfed by splenic macrophages during the first day of transplantation, and before initiation of donor T-cell proliferation. 10 Therefore, there is a possibility that our administration schedule impaired the M-CSF effect on acute and chronic GVHD. The most appropriate administration schedule remains to be clarified.
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